Imfuno entsha ye-Oral COVID-19 Antiviral Medication kunye noVavanyo lweNtsholongwane

A BAMBA isiKhululo sasimahla 5 | eTurboNews | eTN
IAvatar kaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

Okwangoku, i-COVID-19 ikwimeko yobhubhani kwihlabathi liphela. Ukwahluka kweDelta kunye ne-Omicron kuxhaphakile, okukhokelela kuphuculo oluqhubekayo lwesakhono sazo sosulelo. Phakathi kwamaza aphindaphindiweyo e-COVID-19, ukongeza kwisitofu sokugonya se-COVID-19, uphuhliso lwamachiza omlomo asebenzayo e-COVID-19 kunye neendlela zovavanyo ezikhawulezayo, ezilula neziyintshayo ziye zaba yimfuno entsha yothintelo nolawulo lobhubhane. IViva Biotech Holdings kunye ne-XLement, etyalwe yaza yamiliselwa yiViva BioInnovator, izibophelele ekuveliseni amayeza omlomo e-COVID-19 kunye novavanyo lwentsholongwane, inegalelo kumlo ochasene nobhubhani we-COVID-19.

ILanghua Pharmaceutical isayina isivumelwano kunye ne-MPP ukuvelisa into eluhlaza ye-COVID-19 yeyeza lokuthomalalisa iintsholongwane i-molnupiravir.

Jan 2022, iMedicines Patent Pool (MPP) yabhengeza ukuba ityikitye izivumelwano kunye neenkampani ezininzi zokwenza igeneric kuquka iZhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), i-subsidiary yeViva biotech holdings (Viva Biotech (01873.HK)) ukwenzela ukuba ukwenziwa kwamayeza onyango e-COVID-19 e-Molnupiravir kunye nokubonelela kumazwe ali-105 anengeniso ephantsi naphakathi (LMICs) ukuququzelela ufikelelo olufikelelekayo kwihlabathi jikelele lwe-molnupiravir kunye nokuxhasa uthintelo nolawulo lobhubhane. Iinkampani ezintlanu ziya kugxila ekuveliseni izithako ezikrwada, iinkampani ezili-13 ziya kuvelisa zombini isithako esikrwada kunye nechiza eligqityiweyo kwaye iinkampani ezili-9 ziya kuvelisa ichiza eligqityiweyo.

I-Medicines Patent Pool (MPP) ngumbutho wezempilo karhulumente oxhaswa yiZizwe eziManyeneyo osebenza ukwandisa ufikelelo, kwaye uququzelele uphuhliso lwamayeza asindisa ubomi kumazwe anengeniso ephantsi kunye nephakathi. I-MPP kunye ne-MSD, igama lokuthengisa le-Merck & Co., Inc Kenilworth NJ USA yatyikitya isivumelwano selayisenisi ngokuzithandela ngo-Oct 2021. Phantsi kwemiqathango yesivumelwano, i-MPP, ngelayisenisi enikwe yi-MSD, iya kuvunyelwa ukuba iqhubekisele phambili ilayisenisi engabodwa. iilayisenisi eziya kubavelisi (“iLayisensi ye-MPP”) kunye nesiseko sokwenza izinto ezahlukeneyo zonikezelo lwe-molnupiravir eqinisekiswe umgangatho kumazwe aphantsi kweLayisensi ye-MPP, ngokuxhomekeke kugunyaziso lolawulo lwasekhaya.

I-Molnupiravir (MK-4482 kunye ne-EIDD-2801) luhlobo lophando, olulawulwa ngomlomo lwe-analog ye-ribonucleoside enamandla ethintela ukuphindaphinda kwe-SARS-CoV-2 (i-arhente engunobangela we-COVID-19). I-Molnupiravir iphuhliswa yi-MSD ngentsebenziswano ne-Ridgeback Biotherapeutics, liyeza lokuqala elithathwa ngomlomo le-antiviral elifumanekayo kunyango lwe-COVID-19. Idatha evela kwiSigaba sesi-3 i-MOVe-OUT ibonise ukuba unyango lwakwangoko nge-molnupiravir luwunciphise kakhulu umngcipheko wokulaliswa esibhedlele okanye ukusweleka kumngcipheko omkhulu, abantu abadala abangagonywanga abane-COVID-19.

Ngokwe-MPP, iinkampani ezibonelelwe ngelayisenisi zibonise ngempumelelo ukukwazi kwazo ukuhlangabezana neemfuno ze-MPP ezinxulumene nomthamo wemveliso, ukuthotyelwa kwemithetho, kunye nokukwazi ukuhlangabezana nemigangatho yamazwe ngamazwe yamayeza aqinisekisiweyo ngokomgangatho. Ugunyaziso olunikezelwe kwiLanghua Pharmaceutical yi-MPP imele ukuqinisekiswa okuphezulu kunye nokuqatshelwa kwinkqubo yophuhliso kunye nokwandisa ii-APIs, ukubonelela ngokuzinzileyo, i-GMP kunye nenkqubo ye-EHS.

IKhithi yoVavanyo ye-Xlement's COVID-19 iLuphumelele uHlolo lweSebe lezeNzululwazi kunye neTekhnoloji yeRiphabhlikhi yase-China ngempumelelo

Ngomhla wesi-2 kuMatshi ka-2022, i-Xlement, inkampani ezinikeleyo ye-NanoSPR biochip kunye nezixhobo zebhayoloji yenkampani ebikade ityale imali yaze yafukanyelwa yi-Viva BioInnovator, yafumana isaziso sokuphumelela uvavanyo lokusebenza kwi-Ofisi yoMphathiswa wezeNzululwazi nobuChwepheshe kwiRiphabhlikhi yaBantu baseTshayina. Iprojekthi yayo "i-R&D kunye neMveliso yeMisa yeNanoSPR COVID-19 Isixhobo soVavanyo lweNqanaba" yenye yeeprojekthi eziphambili "zoThintelo loMngcipheko woluNtu kunye noLawulo kunye neTekhnoloji yokuPhendula ngokuNgxamisekileyo kunye neZixhobo" inkqubo esebenza indima ebalulekileyo kwi-COVID-19- uphando lwezenzululwazi olunxulumeneyo oluqhubekayo eTshayina. Ngokuphumelela kwayo ekuhlolweni, iXlement's COVID-19 Test Kit nayo iye yaqinisekiswa yiEuropean Union CE ngemveliso enkulu yexesha elizayo kwaye iza kusetyenziswa kungekudala.

Ixhaswe kwitekhnoloji ye-chip ye-NanoSPR ekhethekileyo, i-Xlement iphuhlise ikiti yovavanyo yamasuntswana e-COVID-19, evumela uvavanyo lwenyathelo elinye le-antigens ezininzi zeentsholongwane kwiisampulu ezingama-96 kwimizuzu eli-15, kwaye ubuntununtunu busondele ekuvavanyeni i-antigen enye. Le ndlela ibonisa iinzuzo ezinkulu xa kuthelekiswa neendlela zokuvavanya i-viral nucleic acid ekhoyo: ingasetyenziselwa ukuzivavanya ekhaya, inciphisa ixesha lokuvavanya kakhulu, ngaloo ndlela, inciphisa kakhulu iindleko zokuvavanya i-reagents kunye nomsebenzi. Ngokwamkelwa ngakumbi kobuchwephesha be-NanoSPR kuvavanyo lwe-COVID-19 oluphuhliswe yi-Xlement, silindele ukubona ukuxilongwa kwangoko ngokukhawuleza kweesampulu ezikrokrelekayo kunye novavanyo olukhawulezileyo kwindawo enkulu.

Malunga nombhali

IAvatar kaLinda Hohnholz

Linda Hohnholz

Umhleli oyintloko we eTurboNews esekwe kwi-eTN HQ.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...